Promotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicus

British Journal of Pharmacology

Volumn 149, Issue 5, 2006, Pages 532-541

  Tohda, C ^a   Tamura, T ^a   Matsuyama, S ^a   Komatsu, K ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

A (25 35); Astragali radix; Astragalosides; Astragalus mongholicus; Axon; Dementia; Morris water maze; Neuronal death; Synapse

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; ASTRAGALOSIDE; ASTRAGALUS EXTRACT; ASTRAGALUS MEMBRANACEUS EXTRACT; ASTRAGALUS MONGHOLICUS EXTRACT; SAPONIN; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BRAIN CELL; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; MALE; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER MEMBRANE; NERVE INJURY; NERVE REGENERATION; NEURITE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SPATIAL MEMORY; SYNAPTIC MEMBRANE;

AMYLOID BETA-PROTEIN; ANIMALS; ASTRAGALUS PLANT; AXONS; CELL SURVIVAL; CELLS, CULTURED; COGNITION DISORDERS; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; NERVE GROWTH FACTOR; NEUROFILAMENT PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PLANT EXTRACTS; PLANT ROOTS; RETENTION (PSYCHOLOGY); SAPONINS; SYNAPSES; SYNAPTOPHYSIN; TEMPORAL LOBE; TRITERPENES;

EID: 33750459861     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706865     Document Type: Article

References (25)

1. DeKosky S, Scheff SW (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27: 457-464.
2. Dickson TC, Vickers JC (2001). The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience 105: 99-107.
3. Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523-527.
4. Grace EA, Busciglio J (2003). Aberrant activation of focal adhesion proteins mediates fibrillar amyloid β-induced neuronal dystrophy. J Neuorsci 23: 493-502.
5. Grace EA, Rabiner CA, Busciglio J (2002). Characterization of neuronal dystrophy induced by fibrillar amyloid β: implications for Alzheimer' disease. Neuroscience 114: 265-273.
6. Heinonen O, Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Sorvari H et al. (1995). Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. Neurobiol Aging 16: 505-513.
7. Hiruma H, Katakura T, Takahashi S, Ichikawa T, Kawakami T (2003). Glutamate and amyloid β-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms. J Neurosci 23: 8967-8977.
8. Jackson M, Gentleman S, Lennox L, Ward L, Gray T, Randall K et al. (1995). The cortical neuritic pathology by Huntington's disease. Neuropathol Appl Neurobiol 21: 18-26.
9. Kuboyama T, Tohda C, Komatsu K (2005). Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol 144: 961-971.
10. Kuboyama T, Tohda C, Komatsu K (2006). Withanoside IV and its active metabolite, sominone, attenuate Aβ(25-35)-induced neurodegeneration. Eur J Neurosci 23: 1417-1427.
11. Lei H, Wang B, Li WP, Yang Y, Zhou AW, Chen MZ (2003). Anti-aging effect of astragalosides and its mechanism of action. Acta Pharmacol Sin 24: 230-234.
12. Liberski PP, Budka H (1999). Neuroaxonal pathology in Creutzfeldt-Jakob disease. Acta Neuropathol 97: 329-334.
13. Luo Y, Qin Z, Hong Z, Zhang GX, Ding D, Fu JH et al. (2004). Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. Neurosci Lett 363: 218-223.
14. Mattila PM, Rinne JO, Helenius H, Roytta M (1999). Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol 98: 157-164.
15. Maurice T, Lockhart BP, Privat A (1996). Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181-193.
16. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW (1995). Structure-activity analyses of β-amyloid peptides: contribution of the β25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253-265.
17. Postuma RB, He W, Nunan J, Beyreuther K, Masters CL, Barrow CJ et al. (2000). Substrate-bound β-amyloid peptides inhibit cell adhesion and neurite outgrowth in primary neuronal cultures. J Neurochem 74: 1122-1130.
18. Shi R, He Y, Yi N, Weng S, Cao Y (2001). The regulatory action of Radix Astragali on M-cholinergic receptor of the brain of senile rats. J Tradit Chin Med 21: 232-235.
19. Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R et al. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
20. Tohda C, Kuboyama T, Komatsu K (2005). Search for natural products related to regeneration of the neuronal network. NeuroSignals 14: 34-45.
21. Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K (2004). Aβ(25-35)-induced memory impairment, axonal atrophy and synaptic loss are ameliorated by M1, a metabolite of protopanaxadiol-type saponins. Neuropsycopharmacology 29: 860-868.
22. Tohda C, Tamura T, Komatsu K (2003). Repair of amyloid β(25-35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Res 990: 141-147.
23. Yamada K, Nabeshima T (2000). Animal model of Alzheimer's disease and evaluation of anti-demenria drugs. Pharmacol Ther 88: 93-113.
24. Yankner BA, Duffy LK, Kirschner DA (1990). Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250: 279-282.
25. Zhang W, Benson DL (2001). Stages of synapse development defined by dependence on F-actin. J Neurosci 21: 5169-5181.